Atherosclerosis: On the trail of chemokines;Athérosclérose: sur la piste des chimiokines

Biologie Aujourd'hui

Volumn 204, Issue 4, 2010, Pages 285-293

  Poupel, Lucie ^a   Combadière, Christophe ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

Atherosclerosis; Chemokines; Inflammation; Monocytes

Indexed keywords

CHEMOKINE;

ANIMAL; ARTICLE; ATHEROSCLEROSIS; HUMAN; IMMUNOLOGY; PHYSIOLOGY;

ANIMALS; ATHEROSCLEROSIS; CHEMOKINES; HUMANS;

MURINAE; MUS;

EID: 78651324922     PISSN: 21050678     EISSN: 21050686     Source Type: Journal    
DOI: 10.1051/jbio/2010026     Document Type: Article

References (76)

1. Aiello R.J., Bourassa P.A., Lindsey S.,WengW., Natoli E., Rollins B.J., Milos P.M., Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol, 1999, 19, 1518-1525.
2. Aiello R.J., Perry B.D., Bourassa P.A., Robertson A., Weng W., Knight D.R., Smith A.H., Frederick K.S., Kalgutkar A., Gladue R.P., CCR2 receptor blockade alters blood monocyte subpopulations but does not affect atherosclerotic lesions in apoE(-/-) mice. Atherosclerosis, 2010, 208, 370-375.
3. Aslanian A.M., Charo I.F., Targeted disruption of the scavenger receptor and chemokine CXCL16 accelerates atherosclerosis. Circulation, 2006, 114, 583-590.
4. Auffray C., Fogg D., Garfa M., Elain G., Join-Lambert O., Kayal S., Sarnacki S., Cumano A., Lauvau G., Geissmann F., Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science, 2007, 317, 666-670.
5. ++ monocytes are a major source of TNF. J Immunol, 2002, 168, 3536-3542.
6. Boger C.A., Fischereder M., Deinzer M., Aslanidis C., Schmitz G., Stubanus M., Banas B., Kruger B., Riegger G.A., Kramer B.K., RANTES gene polymorphisms predict all-cause and cardiac mortality in type 2 diabetes mellitus hemodialysis patients. Atherosclerosis, 2005, 183, 121-129.
7. Boisvert W.A., Rose D.M., Johnson K.A., Fuentes M.E., Lira S.A., Curtiss L.K., Terkeltaub R.A., Up-regulated expression of the CXCR2 ligand KC/GRO-alpha in atherosclerotic lesions plays a central role in macrophage accumulation and lesion progression. Am J Pathol, 2006, 168, 1385-1395.
8. BoisvertW.A., Santiago R., Curtiss L.K., Terkeltaub R.A., A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest, 1998, 101, 353-363.
9. -/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature, 1998, 394, 894-897.
10. Breland U.M., Michelsen A.E., Skjelland M., Folkersen L., Krohg-Sorensen K., Russell D., Ueland T., Yndestad A., Paulsson-Berne G., Damas J.K., Oie E., Hansson G.K., Halvorsen B., Aukrust P., Raised MCP-4 levels in symptomatic carotid atherosclerosis: an inflammatory link between platelet and monocyte activation. Cardiovasc Res, 2010, 86, 265-273.
11. Chapman C.M., Beilby J.P., McQuillan B.M., Thompson P.L., Hung J., Monocyte count, but not C-reactive protein or interleukin-6, is an independent risk marker for subclinical carotid atherosclerosis. Stroke, 2004, 35, 1619-1624.
12. Charo I.F., Taubman M.B., Chemokines in the pathogenesis of vascular disease. Circ Res, 2004, 95, 858-866.
13. Combadière C., Potteaux S., Gao J.L., Esposito B., Casanova S., Lee E.J., Debré P., Tedgui A., Murphy P.M., Mallat Z., Decreased Atherosclerotic Lesion Formation in CX3CR1/Apolipoprotein E Double Knockout Mice. Circulation, 2003, 107, 1009-1016. (Pubitemid 36258725)
14. Combadière C., Potteaux S., Rodero M., Simon T., Pezard A., Esposito B., Merval R., Proudfoot A., Tedgui A., Mallat Z., Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation, 2008, 117, 1649-1657.
15. Galkina E., Harry B.L., Ludwig A., Liehn E.A., Sanders J.M., Bruce A., Weber C., Ley K., CXCR6 promotes atherosclerosis by supporting T-cell homing, interferon-gamma production, and macrophage accumulation in the aortic wall. Circulation, 2007, 116, 1801-1811.
16. Geissmann F., Jung S., Littman D.R., Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity, 2003, 19, 71-82.
17. Gonzalez P., Alvarez R., Batalla A., Reguero J.R., Alvarez V., Astudillo A., Cubero G.I., Cortina A., Coto E., Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction. Genes Immun, 2001, 2, 191-195.
18. Gordon S., Taylor P.R., Monocyte and macrophage heterogeneity. Nat Rev Immunol, 2005, 5, 953-964.
19. Greaves D.R., Hakkinen T., Lucas A.D., Liddiard K., Jones E., Quinn C.M., Senaratne J., Green F.R., Tyson K., Boyle J., Shanahan C., Weissberg P.L., Gordon S., Yla-Hertualla S., Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, and thymus- and activation-regulated chemokine, are expressed in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol, 2001, 21, 923-929.
20. Grone H.J., Weber C., Weber K.S., Grone E.F., Rabelink T., Klier C.M., Wells T.N., Proudfood A.E., Schlondorff D., Nelson P.J., Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment. FASEB J, 1999, 13, 1371-1383.
21. Gu L., Okada Y., Clinton S.K., Gerard C., Sukhova G.K., Libby P., Rollins B.J., Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell, 1998, 2, 275-281.
22. Guo J., de Waard V., Van Eck M., Hildebrand R.B., van Wanrooij E.J., Kuiper J., Maeda N., Benson G.M., Groot P.H., Van Berkel T.J., Repopulation of apolipoprotein E knockout mice with CCR2-deficient bone marrow progenitor cells does not inhibit ongoing atherosclerotic lesion development. Arterioscler Thromb Vasc Biol, 2005, 25, 1014-1019.
23. Guo J., Van Eck M., Twisk J., Maeda N., Benson G.M., Groot P.H., Van Berkel T.J., Transplantation of monocyte CC-chemokine receptor 2-deficient bone marrow into ApoE3-Leiden mice inhibits atherogenesis. Arterioscler Thromb Vasc Biol, 2003, 23, 447-453.
24. Ikeda U., Matsui K., Murakami Y., Shimada K., Monocyte chemoattractant protein-1 and coronary artery disease. Clin Cardiol, 2002, 25, 143-147.
25. Kaul S., Bandaru V.C., Suvarna A., Boddu D.B., Stroke burden and risk factors in developing countries with special reference to India. J Indian Med Assoc, 2009, 107, 358, 367-370.
26. Koch A.E., Kunkel S.L., Pearce W.H., Shah M.R., Parikh D., Evanoff H.L., Haines G.K., Burdick M.D., Strieter R.M., Enhanced production of the chemotactic cytokines interleukin-8 and monocyte chemoattractant protein-1 in human abdominal aortic aneurysms. Am J Pathol, 1993, 142, 1423-1431.
27. Kuziel W.A., Dawson T.C., Quinones M., Garavito E., Chenaux G., Ahuja S.S., Reddick R.L., Maeda N., CCR5 deficiency is not protective in the early stages of atherogenesis in apoE knockout mice. Atherosclerosis, 2003, 167, 25-32.
28. Leal J., Luengo-Fernandez R., Gray A., Petersen S., Rayner M., Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J, 2006, 27, 1610-1619. (Pubitemid 43954923)
29. -/- mice reveals a role for fractalkine in atherogenesis. J Clin Invest, 2003, 111, 333-340.
30. Liao F., Berliner J.A., Mehrabian M., Navab M., Demer L.L., Lusis A.J., Fogelman A.M., Minimally modified low density lipoprotein is biologically active in vivo in mice. J Clin Invest, 1991, 87, 2253-2257.
31. Libby P., The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol, 2005, 46, 1225-1228.
32. Ludwig A., Berkhout T., Moores K., Groot P., Chapman G., Fractalkine is expressed by smooth muscle cells in response to IFN-gamma and TNF-alpha and is modulated by metalloproteinase activity. J Immunol, 2002, 168, 604-612.
33. Ludwig A., Weber C., Transmembrane chemokines: versatile "special agents" in vascular inflammation. Thromb Haemost, 2007, 97, 694-703.
34. McDermott D.H., Fong A.M., Yang Q., Sechler J.M., Cupples L.A., Merrell M.N., Wilson P.W., D'Agostino R.B., O'Donnell C.J., Patel D.D., Murphy P.M., Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J Clin Invest, 2003, 111, 1241-1250.
35. McDermott D.H., Halcox J.P., Schenke W.H., Waclawiw M.A., Merrell M.N., Epstein N., Quyyumi A.A., Murphy P.M., Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res, 2001, 89, 401-407.
36. Moatti D., Faure S., Fumeron F., Amara M., Seknadji P., McDermott D.H., Debré P., Aumont M.C., Murphy P.M., de Prost D., Combadière C., Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood, 2001, 97, 1925-1928.
37. Moreau M., Brocheriou I., Petit L., Ninio E., Chapman M.J., Rouis M., Interleukin-8 mediates downregulation of tissue inhibitor of metalloproteinase-1 expression in cholesterol-loaded human macrophages: relevance to stability of atherosclerotic plaque. Circulation, 1999, 99, 420-426.
38. Niessner A., Marculescu R., Haschemi A., Endler G., Zorn G., Weyand C.M., Maurer G., Mannhalter C., Wojta J., Wagner O., Huber K., Opposite effects of CX3CR1 receptor polymorphisms V249I and T280M on the development of acute coronary syndrome. A possible implication of fractalkine in inflammatory activation. Thromb Haemost, 2005, 93, 949-954.
39. Nockher W.A., Scherberich J.E., Expanded CD14+CD16+ monocyte subpopulation in patients with acute and chronic infections undergoing hemodialysis. Infect Immun, 1998, 66, 2782-2790.
40. Nozawa N., Hibi K., Endo M., Sugano T., Ebina T., Kosuge M., Tsukahara K., Okuda J., Umemura S., Kimura K., Association between circulating monocytes and coronary plaque progression in patients with acute myocardial infarction. Circ J, 2010, 74, 1384-1391.
41. Ortlepp J.R., Vesper K., Mevissen V., Schmitz F., Janssens U., Franke A., Hanrath P., Weber C., Zerres K., Hoffmann R., Chemokine receptor (CCR2) genotype is associated with myocardial infarction and heart failure in patients under 65 years of age. J MolMed, 2003, 81, 363-367.
42. Panzer U., Schneider A., Wilken J., Thompson D.A., Kent S.B., Stahl R.A., The chemokine receptor antagonist AOP-RANTES reduces monocyte infiltration in experimental glomerulonephritis. Kidney Int, 1999, 56, 2107-2115.
43. Passlick B., Flieger D., Ziegler-Heitbrock H.W., Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood, 1989, 74, 2527-2534.
44. Petrkova J., Cermakova Z., Drabek J., Lukl J., Petrek M., CC chemokine receptor (CCR)2 polymorphism in Czech patients with myocardial infarction. Immunol Lett, 2003, 88, 53-55.
45. Petrkova J., Cermakova Z., Lukl J., Petrek M., CC chemokine receptor 5 (CCR5) deletion polymorphism does not protect Czech males against early myocardial infarction. J Intern Med, 2005, 257, 564-566.
46. Potteaux S., Combadière C., Esposito B., Casanova S., Merval R., Ardouin P., Gao J.L., Murphy P.M., Tedgui A., Mallat Z., Chemokine receptor CCR1 disruption in bone marrow cells enhances atherosclerotic lesion development and inflammation i n mice. Mol Med, 2005, 11, 16-20.
47. Potteaux S., Combadière C., Esposito B., Lecureuil C., Ait-Oufella H., Merval R., Ardouin P., Tedgui A., Mallat Z., Role of bone marrow-derived CCchemokine receptor 5 in the development of atherosclerosis of low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol, 2006, 26, 1858-1863.
48. Proudfoot A.E., Buser R., Borlat F., Alouani S., Soler D., Offord R.E., Schroder J.M., Power C.A., Wells T.N., Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors. J Biol Chem, 1999, 274, 32478-32485.
49. Proudfoot A.E., Power C.A., Hoogewerf A.J., Montjovent M.O., Borlat F., Offord R.E., Wells T.N., Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem, 1996, 271, 2599-2603.
50. Qiao J.H., Tripathi J., Mishra N.K., Cai Y., Tripathi S., Wang X.P., Imes S., Fishbein M.C., Clinton S.K., Libby P., Lusis A.J., Rajavashisth T.B., Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. Am J Pathol, 1997, 150, 1687-1699.
51. Quinones M.P., Martinez H.G., Jimenez F., Estrada C.A., Dudley M., Willmon O., Kulkarni H., Reddick R.L., Fernandes G., Kuziel W.A., Ahuja S.K., Ahuja S.S., CC chemokine receptor 5 influences late-stage atherosclerosis. Atherosclerosis, 2007, 195, e92-103.
52. Rollins B.J., Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease. Mol Med Today, 1996, 2, 198-204.
53. Ross R., Atherosclerosis-an inflammatory disease. N Engl J Med, 1999, 340, 115-126.
54. -/- mice: evidence for independent chemokine functions in atherogenesis. Circulation, 2008, 117, 1642-1648.
55. Schecter A.D., Rollins B.J., Zhang Y.J., Charo I.F., Fallon J.T., Rossikhina M., Giesen P.L., Nemerson Y., Taubman M.B., Tissue factor is induced by monocyte chemoattractant protein-1 in human aortic smooth muscle and THP-1 cells. J Biol Chem, 1997, 272, 28568-28573.
56. Serbina N.V., Pamer E.G., Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat Immunol, 2006, 7, 311-317.
57. Sheikine Y., Bang C.S., Nilsson L., Samnegard A., Hamsten A., Jonasson L., Eriksson P., Sirsjo A., Decreased plasma CXCL16/SR-PSOX concentration is associated with coronary artery disease. Atherosclerosis, 2006, 188, 462-466. (Pubitemid 44313928)
58. Simeoni E., Winkelmann B.R., Hoffmann M.M., Fleury S., Ruiz J., Kappenberger L., Marz W., Vassalli G., Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosis. Eur Heart J, 2004, 25, 1438-1446.
59. Simmons G., Clapham P.R., Picard L., Offord R.E., Rosenkilde M.M., Schwartz T.W., Buser R., Wells T.N., Proudfoot A.E., Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science, 1997, 276, 276-279.
60. + monocytes in the course of sepsis in neonates and small children: monitoring and functional studies. Scand J Immunol, 2002, 55, 629-638.
61. Stoneman V., Braganza D., Figg N., Mercer J., Lang R., Goddard M., Bennett M., Monocyte/macrophage suppression in CD11b diphtheria toxin receptor transgenic mice differentially affects atherogenesis and established plaques. Circ Res, 2007, 100, 884-893.
62. Sunderkotter C., Nikolic T., Dillon M.J., Van Rooijen N., Stehling M., Drevets D.A., Leenen P.J., Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J Immunol, 2004, 172, 4410-4417.
63. Swirski F.K., Libby P., Aikawa E., Alcaide P., Luscinskas F.W., Weissleder R., Pittet M.J., Ly-6Chi monocytes dominate hypercholesterolemia- associated monocytosis and give rise to macrophages in atheromata. J Clin Invest, 2007, 117, 195-205.
64. Szalai C., Duba J., Prohaszka Z., Kalina A., Szabo T., Nagy B., Horvath L., Csaszar A., Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1-2518 G/G genotype in CAD patients. Atherosclerosis, 2001, 158, 233-239.
65. Tacke F., Alvarez D., Kaplan T.J., Jakubzick C., Spanbroek R., Llodra J., Garin A., Liu J., Mack M., van Rooijen N., Lira S.A., Habenicht A.J., Randolph G.J., Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest, 2007, 117, 185-194.
66. Teupser D., Pavlides S., Tan M., Gutierrez-Ramos J.C., Kolbeck R., Breslow J.L. Major reduction of atherosclerosis in fractalkine (CX3CL1)-deficient mice is at the brachiocephalic artery, not the aortic root. Proc Natl Acad Sci USA, 2004, 101, 17795-17800.
67. Umehara H., Goda S., Imai T., Nagano Y., Minami Y., Tanaka Y., Okazaki T., Bloom E.T., Domae N., Fractalkine, a CX3C-chemokine, functions predominantly as an adhesion molecule in monocytic cell line THP-1. Immunol Cell Biol, 2001, 79, 298-302.
68. Valente A.J., Rozek M.M., Sprague E.A., Schwartz C.J., Mechanisms in intimal monocyte-macrophage recruitment. A special role for monocyte chemotactic protein-1. Circulation, 1992, 86, III20-25.
69. Veillard N.R., Kwak B., Pelli G., Mulhaupt F., James R.W., Proudfoot A.E., Mach F., Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res, 2004, 94, 253-261.
70. Wang J.M., Sica A., Peri G., Walter S., Padura I.M., Libby P., Ceska M., Lindley I., Colotta F., Mantovani A., Expression of monocyte chemotactic protein and interleukin-8 by cytokine-activated human vascular smooth muscle cells. Arterioscler Thromb, 1991, 11, 1166-1174.
71. Weber C., Belge K.U., von Hundelshausen P., Draude G., Steppich B., Mack M., Frankenberger M., Weber K.S., Ziegler-Heitbrock H.W., Differential chemokine receptor expression and function in human monocyte subpopulations. J Leukoc Biol, 2000, 67, 699-704.
72. Wuttge D.M., Zhou X., Sheikine Y., Wagsater D., Stemme V., Hedin U., Stemme S., Hansson G.K., Sirsjo A., CXCL16/SR-PSOX is an interferon-gamma- regulated chemokine and scavenger receptor expressed in atherosclerotic lesions. Arterioscler Thromb Vasc Biol, 2004, 24, 750-755. (Pubitemid 38451615)
73. Yla-Herttuala S., Lipton B.A., Rosenfeld M.E., Sarkioja T., Yoshimura T., Leonard E.J., Witztum J.L., Steinberg D., Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA, 1991, 88, 5252-5256.
74. Yu X., Dluz S., Graves D.T., Zhang L., Antoniades H.N., Hollander W., Prusty S., Valente A.J., Schwartz C.J., Sonenshein G.E., Elevated expression of monocyte chemoattractant protein 1 by vascular smooth muscle cells in hypercholesterolemic primates. Proc Natl Acad Sci USA, 1992, 89, 6953-6957.
75. Zernecke A., Bot I., Djalali-Talab Y., Shagdarsuren E., Bidzhekov K., Meiler S., Krohn R., Schober A., Sperandio M., Soehnlein O., Bornemann J., Tacke F., Biessen E.A., Weber C., Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res, 2008, 102, 209-217.
76. Zernecke A., Shagdarsuren E., Weber C., Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol, 2008, 28, 1897-1908.